XLH Patient Meeting Showcases Value Of Post-Approval Feedback To US FDA
Executive Summary
X-Linked Hypophosphatemia patient feedback meeting follows recent approval of Ultragenyx’ Crysvita. Like an SMA meeting in 2017, it showed how post-approval meetings can help sustain momentum in a new class.
You may also be interested in...
Next Step After 'Right To Try'? Senate Hearing Includes Call To Reopen Orphan Drug Act
Trump Administration’s successful campaign to pass “Right to Try” legislation may be emboldening advocates to push for other policies that will loosen FDA regulatory requirements on rare disease drug development.
Keeping Track: A Fresh Wave Of Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
SMA Patient Meeting Showcases FDA Flexibility – And Appreciation From Advocates
US agency's top neurology review officials received warm reception during Patient Focused Drug Development meeting for Spinal Muscular Atrophy. They also delivered a strong message of continued engagement beyond the first drug approval.